A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants

In vivo T cell depletion with 100 mg alemtuzumab prevents graft‐versus‐host disease (GVHD) in reduced intensity conditioned transplants but is associated with delayed immune reconstitution, a higher risk of infection and relapse. De‐escalation studies have shown that a reduced dose of 30 mg is as ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Jardine, Laura, Publicover, Amy, Bigley, Venetia, Hale, Geoff, Pearce, Kim, Dickinson, Anne, Jackson, Graham, Collin, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737113/
https://www.ncbi.nlm.nih.gov/pubmed/25640315
http://dx.doi.org/10.1111/bjh.13239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737113/
https://www.ncbi.nlm.nih.gov/pubmed/25640315
http://dx.doi.org/10.1111/bjh.13239

Ejemplares similares